Pacientes LMC

🌍 CML Horizons 2026 is almost here! We are looking forward to welcoming CML patient advocates, healthcare professionals, experts and partners from around the world to Tbilisi, Georgia, on 13–15 November 2026! Over three days, we will come together to exchange knowledge, share experiences and explore important topics shaping the future of CML care and advocacy — from access to diagnostics and treatment to emerging therapies, quality of life, shared decision-making and the sustainability of patient organisations. Most importantly, CML Horizons is about connecting our global community, learning from one another and strengthening the patient voice. We look forward to inspiring discussions, meaningful collaborations and another memorable CML Horizons! See you soon in Tbilisi! 🇬🇪 #CMLHorizons2026 #CMLAdvocatesNetwork #PatientAdvocacy #CML #ChronicMyeloidLeukemia

💙 Behind every person living with cancer, there is often someone providing care, strength and support. But caregivers need support too! The National Comprehensive Cancer Network (NCCN) has launched a new FREE resource: NCCN Guidelines for Patients: Caregiving for People with Cancer. 📖 This practical guide offers valuable information and advice to help caregivers navigate the many challenges of supporting a loved one with cancer, including: 💙 Emotional support and well-being 💰 Financial and legal concerns 🏠 Everyday responsibilities and household tasks 🩺 Medical care and treatment management 🔗 Explore and share this free resource: nccn.org/patientresources/pa… Because those who care for others deserve care and support too. 💙 #CMLAdvocatesNetwork #Caregivers #CancerCare #PatientAdvocacy #NCCN #CaregiverSupport

🔬💙 Honouring a scientific discovery that transformed the lives of people living with CML! We are delighted to recognise Dr. Tony Hunter, who has been awarded the 2026 Albany Prize in Medicine and Biomedical Research for his groundbreaking contributions to cancer research. In 1979, Dr. Hunter made a remarkable discovery about how proteins called tyrosine kinases help control cell growth. His work laid the scientific foundation for the development of tyrosine kinase inhibitors (TKIs) — a breakthrough that would change cancer treatment forever. 💊 For people living with chronic myeloid leukaemia (CML), this discovery has a particularly special meaning. It helped pave the way for the development of imatinib, the first TKI approved for CML in 2001, transforming treatment and enabling many patients to live longer, healthier lives. What began as a discovery in a laboratory became a turning point for an entire patient community. 👏 At CML Advocates Network, we celebrate Dr. Hunter's extraordinary contribution to science and recognise the researchers whose dedication continues to bring hope and progress to people living with CML worldwide. Congratulations, Dr. Hunter, and thank you for helping change the future of CML treatment! 💙 🔗 Read more: eurekalert.org/news-releases… #CMLAdvocatesNetwork #CML #TonyHunter #CancerResearch #TKI #MedicalInnovation #PatientAdvocacy